A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 16, 2023

Keywords

ClinConnect Summary

This clinical trial is researching how exercise can help reduce side effects for people receiving treatment for gastrointestinal cancers, like colorectal and esophago/gastric cancers. The goal is to find out what level of aerobic exercise is safe, practical, and beneficial for patients. The study will look at how exercise affects the body's response to treatment, including whether it helps patients stay on track with their therapy and reduces the need for extra medications to manage side effects.

To participate in this study, you need to be at least 18 years old and diagnosed with certain types of locally advanced gastrointestinal cancers. You should also be scheduled to receive chemotherapy and currently do less than 90 minutes of moderate to intense exercise each week. If you join, you can expect to follow specific procedures related to the study, and your exercise levels will be monitored. This trial is actively recruiting participants, so if you are interested, it could be a valuable opportunity to explore the possible benefits of exercise during cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥18 years
• * Diagnosed with colorectal or esophago/gastric solid tumors as defined by one of the following:
• • Histological confirmation
• • As per standard of care imaging
• • Scheduled to receive neoadjuvant chemotherapy or chemotherapy for newly diagnosed metastatic disease
• • Performing ≤90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• • Willingness to comply with all study-related procedures
• • Cleared for exercise participation as per screening clearance via the Physical Activity Readiness Questionnaire
• Exclusion Criteria:
• • Enrollment onto any other lifestyle interventional investigational study, except interventions determined by the PI not to confound study outcomes
• • Receiving treatment for any other diagnosis of invasive cancer
• • Mental impairment leading to inability to cooperate
• • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation